Invitation to FDA Public Meeting

Please take a look all if interested.

Invitation to FDA Public Meeting

PCORI would like to pass on the below invitation that we received from the FDA:

“On behalf of the Food and Drug Administration (FDA), we invite you to an upcoming public meeting on chronic pain to be held July 9, 2018 from 10am to 4pm (EDT) at the FDA Campus in Silver Spring, Maryland. Specific details are outlined below.

The purpose of the meeting is to gather patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies.

This meeting is an exciting opportunity for patients to bring their voice to FDA and the medical product development process. We’re asking you to help make this meeting a success by encouraging patients to participate either in-person or through the live webcast. Please direct individuals with chronic pain, their family members and/or caregivers to the links below to register, and explore the discussion questions and meeting format.

Registration –

https://www.eventbrite.com/e/public-meeting-for-patient-focused-drug-development-on-chronic-pain-registration-44555070415

Meeting website: Public Meeting on Patient-Focused Drug Development for Chronic Pain
Background: Viewing past meeting materials on FDA and Patient-Focused Drug Development in advance may be helpful in preparing for the meeting.

The meeting format maximizes patient participation. For each discussion topic, a small panel of patients or family members will provide brief comments to start the dialogue. The panel comments will be followed by a facilitated discussion with other patients, family members and caregivers in the audience and on the webcast. The majority of the meeting will be devoted to this facilitated discussion. Patients, family members or caregivers who would like to be considered to be on the opening panel can indicate that as part of registration. They will be asked to send a short summary of their responses to the discussion questions (posted on our registration site) to – PatientFocused@fda.hhs.gov

We look forward to this exciting meeting and hope to see you there. If you have any questions, please feel free to contact us at PatientFocused@fda.hhs.gov.”

Thanks all,

Gavin